News for Xenetic Biosciences, Inc. (XBIO)

Strategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND

Revenue increased by 16.1% year-over-year to $0.6 million in Q1 2025. Net loss reported at $0.9 million despite a decrease in operating expenses. Strategic

Xenetic Biosciences reports Q1 2025 highlights: 16.1% revenue growth to $0.6M, $0.9M net loss, and $5.2M cash on hand.

Strategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development progra...

- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at t

Xenetic Biosciences (NASDAQ: XBIO) released a Virtual Investor segment featuring insights from Dr. Reid Bissonnette on their recent poster presentation at the

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on exploratory

Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil ex

FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused

Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the Unive

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in

Xenetic and PeriNess partner for cancer treatment trials

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the

Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Com

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) reported a net loss of $1.2 million for Q1 2024, according to their recent press release.